Bio-Rad Laboratories (BIO-B) Total Non-Current Liabilities (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Total Non-Current Liabilities data on file, last reported at $2.7 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $2.7 billion, up 2.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 2.46% YoY), and the FY2025 annual result was $2.9 billion, up 11.7% from the prior year.
• Total Non-Current Liabilities eased to $2.7 billion in Q1 2026 per BIO-B's latest filing, from $2.9 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $4.0 billion in Q1 2022 and troughed at $2.6 billion in Q4 2024.
• A 5-year average of $3.2 billion and a median of $3.3 billion in 2023 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 29.58% in 2022 and fell as far as 22.85% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $3.7 billion in 2022, then retreated by 8.88% to $3.4 billion in 2023, then retreated by 22.16% to $2.6 billion in 2024, then rose by 11.7% to $2.9 billion in 2025, then retreated by 6.28% to $2.7 billion in 2026.
• Business Quant data shows BIO-B's Total Non-Current Liabilities at $2.7 billion in Q1 2026, $2.9 billion in Q4 2025, and $2.8 billion in Q3 2025.